Trial · NCT05131477
Adverse events952
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 952
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | ABDOMINAL PAIN | Gastrointestinal disorders | 250 mg (500 mg LD) KY1005 (Part 1) | 1 | 77 | 1 |
| other | ABDOMINAL PAIN | Gastrointestinal disorders | 250 mg (no LD) KY1005 (Part 1) | 0 | 78 | 0 |
| other | ABDOMINAL PAIN | Gastrointestinal disorders | 125 mg KY1005 (Part 1) | 1 | 77 | 1 |
| other | ABDOMINAL PAIN | Gastrointestinal disorders | 62.5 mg KY1005 (Part 1) | 0 | 78 | 0 |
| other | ABDOMINAL PAIN | Gastrointestinal disorders | Placebo (Part 1) | 0 | 78 | 0 |
| other | ABDOMINAL PAIN | Gastrointestinal disorders | 250 mg KY1005 Re-Randomized From the 250 mg (LD) Arm (Part 2) | 1 | 13 | 1 |
| other | ABDOMINAL PAIN | Gastrointestinal disorders | Placebo Re-Randomized From the 250 mg (LD) Arm (Part 2) | 0 | 34 | 0 |
| other | ABDOMINAL PAIN | Gastrointestinal disorders | 250 mg KY1005 Re-randomized From the 250 mg (No LD) Arm (Part 2) | 0 | 11 | 0 |
| other | ABDOMINAL PAIN | Gastrointestinal disorders | Placebo Re-Randomized From the 250 mg (No LD) Arm (Part 2) | 0 | 28 | 0 |
| other | ABDOMINAL PAIN | Gastrointestinal disorders | 125 mg KY1005 Re-randomized From the 125 mg Arm (Part 2) | 0 | 12 | 0 |
| other | ABDOMINAL PAIN | Gastrointestinal disorders | Placebo Re-randomized From the 125 mg KY1005 Arm (Part 2) | 0 | 32 | 0 |
| other | ABDOMINAL PAIN | Gastrointestinal disorders | 62.5 mg Re-Randomized From the 62.5 mg KY1005 Arm (Part 2) | 0 | 7 | 0 |
| other | ABDOMINAL PAIN | Gastrointestinal disorders | Placebo Re-randomized From the 62.5 mg Arm (Part 2) | 0 | 34 | 0 |
| other | ABDOMINAL PAIN | Gastrointestinal disorders | Placebo (Part 2) | 0 | 15 | 0 |
| other | ABDOMINAL PAIN UPPER | Gastrointestinal disorders | 250 mg (500 mg LD) KY1005 (Part 1) | 1 | 77 | 1 |
| other | ABDOMINAL PAIN UPPER | Gastrointestinal disorders | 250 mg (no LD) KY1005 (Part 1) | 2 | 78 | 2 |
| other | ABDOMINAL PAIN UPPER | Gastrointestinal disorders | 125 mg KY1005 (Part 1) | 1 | 77 | 1 |
| other | ABDOMINAL PAIN UPPER | Gastrointestinal disorders | 62.5 mg KY1005 (Part 1) | 2 | 78 | 2 |
| other | ABDOMINAL PAIN UPPER | Gastrointestinal disorders | Placebo (Part 1) | 1 | 78 | 1 |
| other | ABDOMINAL PAIN UPPER | Gastrointestinal disorders | 250 mg KY1005 Re-Randomized From the 250 mg (LD) Arm (Part 2) | 0 | 13 | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05131477/events